TN2009000004A1 - Compositions and methods for the treatment of mucormycosis and other fungal diseases - Google Patents

Compositions and methods for the treatment of mucormycosis and other fungal diseases

Info

Publication number
TN2009000004A1
TN2009000004A1 TN2009000004A TN2009000004A TN2009000004A1 TN 2009000004 A1 TN2009000004 A1 TN 2009000004A1 TN 2009000004 A TN2009000004 A TN 2009000004A TN 2009000004 A TN2009000004 A TN 2009000004A TN 2009000004 A1 TN2009000004 A1 TN 2009000004A1
Authority
TN
Tunisia
Prior art keywords
antifungal agent
iron chelating
fungal condition
chelating compound
fungal
Prior art date
Application number
TN2009000004A
Other languages
English (en)
Inventor
Brad J Spellberg
John E Edwards
Ashraf S Ibrahim
Original Assignee
Los Angeles Biomed Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomed Res Inst filed Critical Los Angeles Biomed Res Inst
Publication of TN2009000004A1 publication Critical patent/TN2009000004A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TN2009000004A 2006-07-13 2009-01-12 Compositions and methods for the treatment of mucormycosis and other fungal diseases TN2009000004A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83109906P 2006-07-13 2006-07-13
US89762007P 2007-01-26 2007-01-26
US90407507P 2007-02-27 2007-02-27
PCT/US2007/016065 WO2008008537A2 (fr) 2006-07-13 2007-07-13 Compositions et méthodes pour le traitement de la mucormycose et d'autres maladies fongiques

Publications (1)

Publication Number Publication Date
TN2009000004A1 true TN2009000004A1 (en) 2010-08-19

Family

ID=38610625

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2009000004A TN2009000004A1 (en) 2006-07-13 2009-01-12 Compositions and methods for the treatment of mucormycosis and other fungal diseases

Country Status (18)

Country Link
US (1) US20100129434A1 (fr)
EP (2) EP2412371A1 (fr)
JP (2) JP2009543788A (fr)
KR (1) KR20090036587A (fr)
AU (1) AU2007272781B2 (fr)
BR (1) BRPI0714221A2 (fr)
CA (1) CA2657634A1 (fr)
CL (1) CL2007002026A1 (fr)
IL (1) IL196389A0 (fr)
MA (1) MA30625B1 (fr)
MX (1) MX2009000506A (fr)
NO (1) NO20090565L (fr)
NZ (1) NZ574862A (fr)
RU (1) RU2464024C2 (fr)
SG (1) SG177122A1 (fr)
TN (1) TN2009000004A1 (fr)
TW (1) TWI448285B (fr)
WO (1) WO2008008537A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ614255A (en) * 2009-03-19 2015-03-27 Los Angeles Biomed Res Inst Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
US8980876B2 (en) 2010-10-28 2015-03-17 The Procter & Gamble Company Inhibition of microbial growth by aconitase inhibition
JP2015536970A (ja) * 2012-11-12 2015-12-24 シプラ・リミテッド デフェラシロクス及びデフェリプロンを含む固定用量医薬組成物
WO2014120774A1 (fr) 2013-01-29 2014-08-07 Case Western Reserve University Inhibiteurs de l'acquisition du fer d'origine fongique et utilisations associées
US20160199361A1 (en) * 2013-08-19 2016-07-14 Rutgers, The State University Of New Jersey Method of Inducing An Anti-Retroviral Immune Response By Counter-Acting Retro-Virus Induced Anti-Apoptosis
US20170239182A1 (en) * 2014-08-13 2017-08-24 Mark E. Hayes Pharmaceutical formulations of and methods to prepare chelating agents for efficient metal removal treatment systems
US20170231910A1 (en) * 2014-08-13 2017-08-17 Mark E. Hayes Pharmaceutical formulations of chelating agents as a metal removal treatment system
US11298364B2 (en) * 2015-08-31 2022-04-12 The University Of Adelaide Methods and products for preventing and/or treating microorganism infections comprising iron chelators and non-iron porphyrins
US10960002B2 (en) 2016-05-13 2021-03-30 The Brigham And Women's Hospital, Inc. Volatile metabolite profiles for the diagnosis and treatment of Mucorales fungi
FR3095755A1 (fr) * 2019-05-10 2020-11-13 Balmes Transplantation Nouveaux médicaments cytoprotecteurs
WO2020264076A1 (fr) 2019-06-28 2020-12-30 The Procter & Gamble Company Méthode de traitement augmenté par la lumière

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8329043D0 (en) * 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents
TW349870B (en) * 1993-09-30 1999-01-11 Janssen Pharmaceutica Nv An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
MY129541A (en) 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
WO1999009997A1 (fr) * 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Edta et autres agents chelatants associes ou non a des agents antimicrobiens, antifongiques, utilises pour la prevention et le traitement des mycoses
DE50111949D1 (de) * 2000-12-16 2007-03-15 Alstom Technology Ltd Komponente einer Strömungsmaschine
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
ITMI20022447A1 (it) * 2002-11-19 2004-05-20 Carlo Ghisalberti Uso di piridinoni nel trattamento della purpura capillare ed affezioni cutanee correlate.
MXPA05007156A (es) * 2002-12-31 2005-09-21 Nektar Therapeutics Formulacion farmaceuticas aerosolizable para terapia para infecciones fungicas.
WO2004108114A2 (fr) * 2003-03-31 2004-12-16 Dinesh Shantilal Patel Composition antifongique et son procede de fabrication
DE10356409B4 (de) * 2003-11-28 2006-12-28 Biofrontera Discovery Gmbh Neues Arzneimittel Oxachelin und Derivate

Also Published As

Publication number Publication date
BRPI0714221A2 (pt) 2013-01-01
MA30625B1 (fr) 2009-08-03
TWI448285B (zh) 2014-08-11
SG177122A1 (en) 2012-01-30
CL2007002026A1 (es) 2008-06-06
KR20090036587A (ko) 2009-04-14
EP2043636A2 (fr) 2009-04-08
AU2007272781A1 (en) 2008-01-17
US20100129434A1 (en) 2010-05-27
AU2007272781B2 (en) 2012-10-18
TW200816994A (en) 2008-04-16
WO2008008537A3 (fr) 2008-04-24
NO20090565L (no) 2009-03-30
IL196389A0 (en) 2009-09-22
JP2013040212A (ja) 2013-02-28
MX2009000506A (es) 2009-05-20
EP2412371A1 (fr) 2012-02-01
RU2009104961A (ru) 2010-08-20
JP2009543788A (ja) 2009-12-10
CA2657634A1 (fr) 2008-01-17
RU2464024C2 (ru) 2012-10-20
WO2008008537A2 (fr) 2008-01-17
NZ574862A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
TN2009000004A1 (en) Compositions and methods for the treatment of mucormycosis and other fungal diseases
NZ597489A (en) Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006093348A3 (fr) Procede et composition destines au traitement des maladies vasculaires peripheriques
EP2512479A4 (fr) Méthodes et compositions destinées au traitement de maladies vasculaires périphériques
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
TW200639159A (en) Treatment of pain
WO2011047439A8 (fr) Nouvelle thérapie antiparasitaire
WO2008079270A3 (fr) Coadministration d'alpha-foetoprotéine et d'un agent immunomodulateur pour traiter la sclérose en plaques
WO2007128526A3 (fr) Méthodes de traitement des maladies néovasculaires
MX2010007584A (es) Inhibidores de proteina cinasa y uso de los mismos.
MY150682A (en) Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
WO2010032011A3 (fr) Thérapie antifongique
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
TW200742580A (en) Methods for treating nephrolithiasis
WO2007015841A3 (fr) Procede permettant de traiter la preeclampsie
WO2011153458A3 (fr) Compositions et méthodes utilisables en vue de l'inhibition ou du traitement d'une infection par le virus de la dengue
WO2008077062A3 (fr) Suppression de la réactivation de la stat3 après inhibition de la kinase src pour le traitement du cancer
WO2006101909A3 (fr) Polytherapies pour le traitement ou la prevention de maladies
WO2007136615A3 (fr) Thérapie anticancéreuse combinée
UA96736C2 (ru) Ингибиторы pi3k для лечения эндометриоза
WO2002055022A3 (fr) Metabolite actif de compose antifongique
NO20035038D0 (no) Forhindring av avhengighet ved smertebehandling
WO2008016665A3 (fr) Composés et méthodes de traitement de troubles médiés par flt3